TriangleDISEASE & TREATMENT SETTING
Acute Lymphoblastic Leukemia
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Acute Lymphoblastic Leukemia
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Acute Lymphoblastic Leukemia. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
21 more-specific settings
Arranon: refractory acute lymphoblastic leukemia after prior therapy →Blincyto: refractory acute lymphoblastic leukemia →Clolar: refractory acute lymphocytic leukemia after prior therapy →KYMRIAH: refractory acute lymphoblastic leukemia →Mercaptopurine: acute lymphoblastic leukemia (maintenance) →Besponsa: refractory acute lymphoblastic leukemia →JYLAMVO: refractory acute lymphoblastic leukemia (maintenance) →Leukine: acute lymphoblastic leukemia after prior therapy →Xatmep: acute lymphoblastic leukemia (maintenance) →PURIXAN: acute lymphoblastic leukemia (maintenance) →Doxorubicin Hydrochloride: metastatic acute lymphoblastic leukemia →ONCASPAR: acute lymphoblastic leukemia (first-line) →Arranon: recurrent acute lymphoblastic leukemia after prior therapy →Arranon: recurrent acute lymphoblastic leukemia after prior therapy →IMKELDI: refractory acute lymphoblastic leukemia →Methotrexate: acute lymphoblastic leukemia after prior therapy →TECARTUS: refractory acute lymphoblastic leukemia →Gleevec: refractory acute lymphoblastic leukemia →AUCATZYL: refractory acute lymphoblastic leukemia →Acute Lymphoblastic Leukemia →recurrent Acute Lymphoblastic Leukemia →
Study evidence for this setting
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogeno
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed Hig
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Post Transplant Donor Lymphocyte Infusion
Stem Cell Transplant for Hematological Malignancy
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Indication-specific source history
2004-12-28 · Clolar (clofarabine) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-37008445d0a4c276
- event date
- 2004-12-28
- event kind
- accelerated-approval
- drug or regimen
- Clolar (clofarabine)
- source indication text
- Treatment of pediatric patients 1 to 21 yrs old with relapsed or refractory acute lymphocytic leukemia (ALL) after at least 2 prior regimens
- match phrase
- acute lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b4cfcec756106ccaedb8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2005-10-28 · Arranon (nelarabine) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-d3d8bdae0842b433
- event date
- 2005-10-28
- event kind
- accelerated-approval
- drug or regimen
- Arranon (nelarabine)
- source indication text
- Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f58aef392b7fc74222f1
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2012-12-14 · Iclusig (ponatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-108760cbb44327a3
- event date
- 2012-12-14
- event kind
- accelerated-approval
- drug or regimen
- Iclusig (ponatinib)
- source indication text
- Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-207b1271c5e76362e54d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2014-12-03 · Blincyto (blinatumomab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-e67e34379a36dfdb
- event date
- 2014-12-03
- event kind
- accelerated-approval
- drug or regimen
- Blincyto (blinatumomab)
- source indication text
- Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-82907dc69f86ffd38c79
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2016-11-28 · Iclusig (ponatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-89a66bf821990fc4
- event date
- 2016-11-28
- event kind
- traditional-approval
- drug or regimen
- Iclusig (ponatinib)
- source indication text
- Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-207b1271c5e76362e54d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-07-11 · Blincyto (blinatumomab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-bd3e064bf368c79b
- event date
- 2017-07-11
- event kind
- traditional-approval
- drug or regimen
- Blincyto (blinatumomab)
- source indication text
- Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-82907dc69f86ffd38c79
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2018-03-29 · Blincyto (blinatumomab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-d54672791d176b57
- event date
- 2018-03-29
- event kind
- accelerated-approval
- drug or regimen
- Blincyto (blinatumomab)
- source indication text
- Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children 1
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-02f492ec41663fb81dfc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-07-31 · Arranon (nelarabine) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-eff4f805d1d9d834
- event date
- 2019-07-31
- event kind
- traditional-approval
- drug or regimen
- Arranon (nelarabine)
- source indication text
- Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f58aef392b7fc74222f1
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-07-18 · Clolar (clofarabine) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-6d945af322317a63
- event date
- 2022-07-18
- event kind
- traditional-approval
- drug or regimen
- Clolar (clofarabine)
- source indication text
- Treatment of pediatric patients 1 to 21 yrs old with relapsed or refractory acute lymphocytic leukemia (ALL) after at least 2 prior regimens
- match phrase
- acute lymphocytic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b4cfcec756106ccaedb8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-06-20 · Blincyto (blinatumomab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-785ccbcbc3fd8863
- event date
- 2023-06-20
- event kind
- traditional-approval
- drug or regimen
- Blincyto (blinatumomab)
- source indication text
- Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children 1
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-02f492ec41663fb81dfc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-03-19 · Iclusig (ponatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- event id
- fda-6cc8ad68ff376d34
- event date
- 2024-03-19
- event kind
- accelerated-approval
- drug or regimen
- Iclusig (ponatinib)
- source indication text
- Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
- match phrase
- acute lymphoblastic leukemia
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-aeff872fb7dd4814dd77
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-lymphoblastic-leukemia
- binding id
- ncit-C3167
- source collection
- ncit-concept
- source key
- C3167
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice